Emma Rusmayani
Research Subjects
Emma Rusmayani has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Viona Viona
Department of Research JEC Eye Hospitals and Clinics, Jakarta, Indonesia
2 shared publications Johan A Hutauruk
Jakarta Eye Center, Jakarta, Indonesia
1 shared publication- Muhammad Bayu Sasongko
Department of Ophthalmology, Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
1 shared publication Suhardjo
Ophthalmology Department, Faculty of Medicine University Gadjah Mada, Yogyakarta, Indonesia
1 shared publicationWidya Artini
Glaucoma Department, Jakarta Eye Center Hospitals and Clinics, Jakarta, Indonesia
1 shared publication
Latest Publications
- Open Access
- 1 March 2023
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. ume 16, 179-185
Challenges in Managing Secondary Glaucoma Post-Repeat Penetrating Keratoplasty in a Developing Country
Purpose: To illustrate the complexity in managing secondary glaucoma post-repeat penetrating keratoplasty in a developing country. Case Description: A patient with a history of five repeat penetrating keratoplasties (PKPs) showed good intraocular pressure (IOP) control with trabeculectomy; however, blebitis occurred as an undesirable complication. Trabeculectomy was done rather than tube implantation due to socioeconomic factors, although it’s not an ideal treatment. After the infection subsided, we performed a bleb revision with a scleral patch graft. Intraocular pressure was high in the follow-up period after the scleral patch, therefore we decided to do tube implantation. Following glaucoma tube implant surgery, the patient had good IOP control and a clear graft after six months of follow-up. Conclusion: Secondary glaucoma post repeat PKPs is challenging in both diagnosis and management. Immediate action is imperative to control IOP, prevent glaucoma progression, and minimize corneal graft damage. In addition to medical reasons, socioeconomic factors should be considered.
- 1 March 2023
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. ume 16, 179-185
Open AccessChallenges in Managing Secondary Glaucoma Post-Repeat Penetrating Keratoplasty in a Developing Country
Purpose: To illustrate the complexity in managing secondary glaucoma post-repeat penetrating keratoplasty in a developing country. Case Description: A patient with a history of five repeat penetrating keratoplasties (PKPs) showed good intraocular pressure (IOP) control with trabeculectomy; however, blebitis occurred as an undesirable complication. Trabeculectomy was done rather than tube implantation due to socioeconomic factors, although it’s not an ideal treatment. After the infection subsided, we performed a bleb revision with a scleral patch graft. Intraocular pressure was high in the follow-up period after the scleral patch, therefore we decided to do tube implantation. Following glaucoma tube implant surgery, the patient had good IOP control and a clear graft after six months of follow-up. Conclusion: Secondary glaucoma post repeat PKPs is challenging in both diagnosis and management. Immediate action is imperative to control IOP, prevent glaucoma progression, and minimize corneal graft damage. In addition to medical reasons, socioeconomic factors should be considered.
- Open Access
- 10 December 2022
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 16, 4075-4087
A Novel Biomarker in Primary Glaucoma: Aqueous Humor and Serum Levels of Ischemia Modified Albumin (IMA)
Purpose: To analyze ischemia-modified albumin (IMA) levels in aqueous humor and serum, and their correlation to RNFL thinning in primary glaucoma patients. Design: Cross-sectional study. Methods: Patients were divided into the control and glaucoma groups. The control group was patients with senile cataracts. The glaucoma group consisted of patients diagnosed for the first time as primary open-angle glaucoma (POAG) or primary angle closure glaucoma (PACG). Exclusion criteria were secondary glaucoma and patients with systemic disease. A complete cataract examination was done for all patients, and glaucoma examinations for the glaucoma group. In both groups, the IMA aqueous humor was obtained during cataract and glaucoma procedure. Serum levels of IMA, malondialdehyde (MDA), and tumor necrosis factor alpha (TNF-α) were examined during preoperative examinations. Results: Control group comprised 33 participants, and glaucoma group 41 patients (21 PACG and 20 POAG). Mean IMA aqueous humor (AQH) levels found in cataract group 6.039± 3.16 ng/mL, glaucoma group 14.89± 6.08 ng/mL, PACG group 12.69± 6.25 ng/mL and POAG group 17.33± 4.988 mg/mL. Mean IMA serum levels in cataract group 14.75± 6.53 ng/mL, glaucoma group 13.89± 6.53 ng/mL, PACG group 12.79± 6.46 ng/mL± and POAG group 14.93± 10.74 ng/mL. Glaucoma group had significant higher level of IMA in aqueous humor compared to control group, but opposite findings in serum IMA levels between groups. POAG patients had a higher aqueous IMA level compared to PACG group and correlated significantly with IOP. IMA AQH also negatively correlated to the RNFL thickness in both POAG and PACG group. Cut off 9.5 ng/mL was considered as a normal limit value to differentiate between control and glaucoma group. Conclusion: Primary glaucoma patients showed a significantly increased level of IMA AQH as a local ischemic biomarker compared to the control group. Systemic oxidative activity is not a representation of local ocular oxidative stress in both cataract and glaucoma group.
- 10 December 2022
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 16, 4075-4087
Open AccessA Novel Biomarker in Primary Glaucoma: Aqueous Humor and Serum Levels of Ischemia Modified Albumin (IMA)
Purpose: To analyze ischemia-modified albumin (IMA) levels in aqueous humor and serum, and their correlation to RNFL thinning in primary glaucoma patients. Design: Cross-sectional study. Methods: Patients were divided into the control and glaucoma groups. The control group was patients with senile cataracts. The glaucoma group consisted of patients diagnosed for the first time as primary open-angle glaucoma (POAG) or primary angle closure glaucoma (PACG). Exclusion criteria were secondary glaucoma and patients with systemic disease. A complete cataract examination was done for all patients, and glaucoma examinations for the glaucoma group. In both groups, the IMA aqueous humor was obtained during cataract and glaucoma procedure. Serum levels of IMA, malondialdehyde (MDA), and tumor necrosis factor alpha (TNF-α) were examined during preoperative examinations. Results: Control group comprised 33 participants, and glaucoma group 41 patients (21 PACG and 20 POAG). Mean IMA aqueous humor (AQH) levels found in cataract group 6.039± 3.16 ng/mL, glaucoma group 14.89± 6.08 ng/mL, PACG group 12.69± 6.25 ng/mL and POAG group 17.33± 4.988 mg/mL. Mean IMA serum levels in cataract group 14.75± 6.53 ng/mL, glaucoma group 13.89± 6.53 ng/mL, PACG group 12.79± 6.46 ng/mL± and POAG group 14.93± 10.74 ng/mL. Glaucoma group had significant higher level of IMA in aqueous humor compared to control group, but opposite findings in serum IMA levels between groups. POAG patients had a higher aqueous IMA level compared to PACG group and correlated significantly with IOP. IMA AQH also negatively correlated to the RNFL thickness in both POAG and PACG group. Cut off 9.5 ng/mL was considered as a normal limit value to differentiate between control and glaucoma group. Conclusion: Primary glaucoma patients showed a significantly increased level of IMA AQH as a local ischemic biomarker compared to the control group. Systemic oxidative activity is not a representation of local ocular oxidative stress in both cataract and glaucoma group.